Squamous cell carcinoma of the anal canal
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-ANAL-SCC |
|---|---|
| Type | Disease |
| Aliases | Anal canal SCCAnal carcinomaAnal squamous cell carcinoma (Anal SCC)Cancer of the anusSCCASquamous cell carcinoma of the anusПлоскоклітинний рак анального каналу |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_10 | C21.0 |
|---|---|
| icd_o_3_morphology | 8070/3 |
| icd_o_3_topography | ["C21.0", "C21.1", "C21.2"] |
| oncotree_code | ANSC |
Notes
Anal SCC is HPV-driven (90%) and highly curable in locally advanced stages (~75-85%) with organ-preserving chemoradiation. The Nigro protocol (mitomycin C + 5-FU + RT) is NCCN Category 1 — APR is NOT standard initial treatment. Response assessment at 8-11 weeks post-CRT; confirm residual disease by biopsy before salvage APR. HIV+ patients require same CRT with antiretroviral optimization. Screening: high-resolution anoscopy for HIV+ patients and MSM is recommended.
Used By
Algorithms
ALGO-ANAL-SCC-1L- ALGO-ANAL-SCC-1L
Disease
DIS-PENILE-SCC- Penile squamous cell carcinomaDIS-VULVAR-VAGINAL-SCC- Vulvar and vaginal squamous cell carcinoma
Indication
IND-ANAL-SCC-LA-1L-NIGRO-CRT- IND-ANAL-SCC-LA-1L-NIGRO-CRTIND-ANAL-SCC-METASTATIC-1L-CARBO-PACLI- IND-ANAL-SCC-METASTATIC-1L-CARBO-PACLIIND-ANAL-SCC-METASTATIC-1L-RETIFANLIMAB-CARBO-PACLI- IND-ANAL-SCC-METASTATIC-1L-RETIFANLIMAB-CARBO-PACLI
Procedures
PROC-HRA-HIGH-RES-ANOSCOPY- High-resolution anoscopy (HRA) for anal HSIL surveillance
Questionnaires
QUEST-ANAL-SCC-1L-STUB- Anal squamous cell carcinoma (Anal SCC) — first line
Red flag
RF-CHRONIC-HPV-MALIGNANCY-PREVENTION- Persistent high-risk HPV infection (HPV-16, 18, 31, 33, 45, 52, 58 detected on cervical c...RF-IATROGENIC-TRANSPLANT-IMMUNOSUPPRESSION-LONGTERM-PREVENTION- Solid-organ transplant recipient on chronic immunosuppression ≥3 years post-transplant, b...
Regimen
REG-CARBO-PACLI-ANAL-MET- Carboplatin + paclitaxel (anal carcinoma, metastatic)REG-NIGRO-MMC-5FU-RT- Nigro protocol (mitomycin-C + 5-FU + RT, anal SCC)
Sources
SRC-ACT2-JAMES-2013- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatm...SRC-NCCN-ANAL-2025- NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma